Skip to content

Does Medical Cannabis Reduce Opioid Use in Adults With Pain

CompletedNCT04308148
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

The study will examine how medical cannabis use affects opioid analgesic use. This landmark study will be among the first to examine the effect of medical cannabis with different THC/CBD (Tetrahydrocannibinol/Cannabidiol) content on opioid use as well as adverse events.

Study details

Official title
Does Medical Cannabis Reduce Opioid Use in Adults With Pain: An Observational Study
Conditions
Sponsor
Albert Einstein College of Medicine
Collaborators
Laura and John Arnold Foundation; Vireo Health
Start date
2020-10-06
Primary completion
2024-03-13
Sex
All
Age range
from 18 Years to 99 Years
Results posted
No results posted in this snapshot
Countries
United States
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * At least 18 years of age * English or Spanish fluency * Actively certified for medical cannabis * Intends to have a soft-gel capsule product dispensed at Vireo * Medical cannabis qualifying conditions or complications of "chronic or severe pain" or "pain that degrades health and functional capability as an alternative to opioid use or substance use disorder" * Joint or neuropathic pain * Current severe pain * Dispensed opioid analgesics within the last 60 days To maintain the integrity of the study, we do not disclose all inclusion criteria to potential participants. Exclusion Criteria: * Inability to provide informed consent * Inability to complete study visits over 14 weeks * Terminal illness * Current or prior psychotic disorder * Buprenorphine or methadone treatment for opioid use disorder within the past year * Allergies to tapioca or coconut * Currently pregnant, planning to become pregnant within the next 3 months, or breastfeeding * Condition that is considered by a pharmacist or medical provider to be a contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific drug-use interaction)

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04308148